NASDAQ:PHVS Pharvaris (PHVS) Stock Forecast, Price & News $20.87 +0.60 (+2.96%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$19.86▼$21.0050-Day Range$16.26▼$21.4052-Week Range$1.77▼$26.86Volume32,619 shsAverage Volume43,407 shsMarket Capitalization$664.50 millionP/E RatioN/ADividend YieldN/APrice Target$23.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Pharvaris MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside10.2% Upside$23.00 Price TargetShort InterestHealthy0.11% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.88Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.46) to ($2.32) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.92 out of 5 starsMedical Sector705th out of 972 stocksPharmaceutical Preparations Industry328th out of 444 stocks 2.5 Analyst's Opinion Consensus RatingPharvaris has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.00, Pharvaris has a forecasted upside of 10.2% from its current price of $20.87.Amount of Analyst CoveragePharvaris has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.11% of the float of Pharvaris has been sold short.Short Interest Ratio / Days to CoverPharvaris has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pharvaris has recently decreased by 22.05%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPharvaris does not currently pay a dividend.Dividend GrowthPharvaris does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PHVS. Previous Next 2.7 News and Social Media Coverage News SentimentPharvaris has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Pharvaris this week, compared to 1 article on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pharvaris insiders have not sold or bought any company stock.Percentage Held by Insiders11.84% of the stock of Pharvaris is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Pharvaris are expected to grow in the coming year, from ($2.46) to ($2.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pharvaris is -7.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pharvaris is -7.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPharvaris has a P/B Ratio of 4.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Pharvaris (NASDAQ:PHVS) StockPharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.Read More PHVS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PHVS Stock News HeadlinesSeptember 29, 2023 | americanbankingnews.comPharvaris (NASDAQ:PHVS) Expected to Post Q3 2023 Earnings of ($0.62) Per ShareSeptember 26, 2023 | msn.comWedbush Initiates Coverage of Pharvaris (PHVS) with Outperform RecommendationOctober 1, 2023 | Oxford Club (Ad)Better Than Oil StocksThe best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. September 26, 2023 | americanbankingnews.comPharvaris (NASDAQ:PHVS) Receives New Coverage from Analysts at WedbushSeptember 25, 2023 | markets.businessinsider.comPharvaris' Promising Oral Treatment Solutions For Treating Swollen Blood Vessels - Analyst Sees 35% UpsideSeptember 19, 2023 | finance.yahoo.comPharvaris To Participate in the 2023 Cantor Global Healthcare ConferenceSeptember 14, 2023 | thestreet.comPharvaris N.V.September 6, 2023 | finance.yahoo.comPharvaris To Participate in the Morgan Stanley 21st Annual Global Healthcare ConferenceOctober 1, 2023 | Oxford Club (Ad)Better Than Oil StocksThe best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. September 6, 2023 | finance.yahoo.comPharvaris To Present at the 18th German Allergy CongressAugust 31, 2023 | msn.comPharvaris (PHVS) Price Target Increased by 22.58% to 22.15August 28, 2023 | finance.yahoo.comWe're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn RateAugust 23, 2023 | finance.yahoo.comPharvaris To Present at the 2023 HAEi Regional Conference EMEAAugust 15, 2023 | msn.comMorgan Stanley ups Pharvaris to overweight, citing HAE drug prospectsAugust 15, 2023 | markets.businessinsider.com8 Analysts Have This to Say About PharvarisAugust 15, 2023 | msn.comMorgan Stanley Upgrades Pharvaris (PHVS)August 15, 2023 | cnbc.comMorgan Stanley says this under-the-radar biotech stock can rally more than 80%August 7, 2023 | finance.yahoo.comPharvaris Reports Second Quarter 2023 Financial Results and Provides Business UpdateJuly 27, 2023 | seekingalpha.comPharvaris: FDA Lifts Clinical Hold, Progresses HAE Drug DevelopmentJuly 21, 2023 | finance.yahoo.comPharvaris Presents Clinical Data at the 2023 U.S. HAEA National SummitJuly 17, 2023 | markets.businessinsider.comAnalyst Expectations for Pharvaris's FutureJuly 10, 2023 | markets.businessinsider.comMorgan Stanley Keeps Their Hold Rating on Pharvaris (PHVS)July 6, 2023 | msn.comPharvaris (PHVS) Price Target Increased by 6.90% to 18.07July 3, 2023 | finance.yahoo.comPharvaris N.V.'s (NASDAQ:PHVS) largest shareholders are private equity firms with 50% ownership, institutions own 18%June 27, 2023 | finance.yahoo.comWhy Shares of Pharvaris N.V. Are Up TuesdayJune 26, 2023 | markets.businessinsider.com5 Analysts Have This to Say About PharvarisJune 26, 2023 | msn.comPharvaris stock climbs 13% after FDA lifts hold on HAE drug candidateSee More Headlines Receive PHVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharvaris and its competitors with MarketBeat's FREE daily newsletter. Email Address PHVS Company Calendar Last Earnings8/07/2023Today9/30/2023Next Earnings (Estimated)12/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PHVS CUSIPN/A CIK1830487 Webwww.pharvaris.com Phone31-71-203-6410FaxN/AEmployees68Year FoundedN/APrice Target and Rating Average Stock Price Forecast$23.00 High Stock Price Forecast$34.00 Low Stock Price Forecast$16.00 Forecasted Upside/Downside+10.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-80,420,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.57% Return on Assets-51.80% Debt Debt-to-Equity RatioN/A Current Ratio11.89 Quick Ratio11.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.94 per share Price / Book4.22Miscellaneous Outstanding Shares31,840,000Free FloatN/AMarket Cap$664.50 million OptionableNot Optionable Beta-3.83 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Berndt Axel Edvard Modig CPA (Age 64)M.B.A., MBA, Co-Founder, CEO & Exec. Director Comp: $534.85kDr. Jochen Knolle Ph.D. (Age 73)Chief Scientific Officer & COO Ms. Anna Nijdam M.Sc. (Age 42)R.A., Head of Strategic Fin. & Principal Accounting Officer Ms. Joan Schmidt J.D. (Age 59)Chief Legal Officer Dr. Peng Lu M.D. (Age 45)Ph.D., Chief Medical Officer Dr. Anne A. Lesage Ph.D. (Age 62)Chief Early Devel. Officer Dr. Morgan Conn Ph.D. (Age 54)Chief Bus. Officer Mr. Wim Souverijns Ph.D. (Age 52)Chief Community Engagement & Commercial Officer Maryann CiminoDirector of Corp. RelationsMs. Annick Deschoolmeester (Age 50)Chief HR Officer More ExecutivesKey CompetitorsAptinyxNASDAQ:APTXGH ResearchNASDAQ:GHRSInterCureNASDAQ:INCRLAVA TherapeuticsNASDAQ:LVTXNLS PharmaceuticsNASDAQ:NLSPView All CompetitorsInstitutional OwnershipBain Capital Life Sciences Investors LLCBought 1,688,183 shares on 8/15/2023Ownership: 0.000%venBio Partners LLCBought 1,986,097 shares on 8/15/2023Ownership: 0.000%Silverarc Capital Management LLCSold 359,387 shares on 8/15/2023Ownership: 0.000%Walleye Capital LLCSold 39,619 shares on 8/15/2023Ownership: 0.000%Cormorant Asset Management LPBought 157,154 shares on 8/14/2023Ownership: 0.000%View All Institutional Transactions PHVS Stock - Frequently Asked Questions Should I buy or sell Pharvaris stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pharvaris in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PHVS shares. View PHVS analyst ratings or view top-rated stocks. What is Pharvaris' stock price forecast for 2023? 5 brokerages have issued 1 year target prices for Pharvaris' stock. Their PHVS share price forecasts range from $16.00 to $34.00. On average, they anticipate the company's share price to reach $23.00 in the next twelve months. This suggests a possible upside of 10.2% from the stock's current price. View analysts price targets for PHVS or view top-rated stocks among Wall Street analysts. How have PHVS shares performed in 2023? Pharvaris' stock was trading at $11.25 at the beginning of 2023. Since then, PHVS stock has increased by 85.5% and is now trading at $20.87. View the best growth stocks for 2023 here. Are investors shorting Pharvaris? Pharvaris saw a decrease in short interest during the month of September. As of September 15th, there was short interest totaling 15,200 shares, a decrease of 22.1% from the August 31st total of 19,500 shares. Based on an average daily volume of 68,900 shares, the short-interest ratio is currently 0.2 days. Approximately 0.1% of the company's stock are short sold. View Pharvaris' Short Interest. When is Pharvaris' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, December 14th 2023. View our PHVS earnings forecast. How were Pharvaris' earnings last quarter? Pharvaris (NASDAQ:PHVS) announced its quarterly earnings results on Monday, August, 7th. The company reported ($0.69) EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $0.02. When did Pharvaris IPO? (PHVS) raised $126 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, BofA Securities and SVB Leerink served as the underwriters for the IPO and Oppenheimer & Co. and Kempen & Co. were co-managers. What is Pharvaris' stock symbol? Pharvaris trades on the NASDAQ under the ticker symbol "PHVS." How do I buy shares of Pharvaris? Shares of PHVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Pharvaris' stock price today? One share of PHVS stock can currently be purchased for approximately $20.87. How much money does Pharvaris make? Pharvaris (NASDAQ:PHVS) has a market capitalization of $664.50 million. The company earns $-80,420,000.00 in net income (profit) each year or ($2.84) on an earnings per share basis. How can I contact Pharvaris? The official website for the company is www.pharvaris.com. The company can be reached via phone at 31-71-203-6410 or via email at sarah.mccabe@sternir.com. This page (NASDAQ:PHVS) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.